12.12
Beta Bionics Inc Aktie (BBNX) Neueste Nachrichten
BBNX Maintained by Goldman Sachs -- Price Target Lowered to $17. - GuruFocus
Goldman Sachs Maintains Beta Bionics(BBNX.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Beta Bionics | 4: Statement of changes in beneficial ownership of securities-Director Jones Christy - Moomoo
Beta Bionics | 4: Statement of changes in beneficial ownership of securities-Director CARNEY SEAN - Moomoo
Beta Bionics director Jones Christy sells $19,880 in stock By Investing.com - Investing.com Nigeria
Beta Bionics director Adam Lezack sells $21,137 in stock By Investing.com - Investing.com India
Beta Bionics director Adam Lezack sells $21,137 in stock - Investing.com
Director at Beta Bionics (BBNX) receives 16,965-share equity award - Stock Titan
Beta Bionics (BBNX) director logs stock grant and 1,998-share sale - Stock Titan
Beta Bionics (BBNX) director receives 16,965-share equity award - Stock Titan
Beta Bionics (BBNX) director receives 16,965-share restricted stock unit grant - Stock Titan
Beta Bionics (BBNX) director awarded 16,965 restricted stock units - Stock Titan
Beta Bionics (BBNX) director gets stock grant, sells 1,998 shares under plan - Stock Titan
Beta Bionics to launch its first insulin patch pump to compete with Insulet - MedTech Dive
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Beta Bionics, Inc. (BBNX) and Twist Bioscience (TWST) - The Globe and Mail
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Raises Target Price to $13 - Moomoo
Piper Sandler Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Beta Bionics | 8-K: Current report - Moomoo
Beta Bionics (NASDAQ: BBNX) investors approve directors and auditor - Stock Titan
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development - Sahm
Beta Bionics Expects Commercialization of Mint Insulin Patch Pump in 2027 - Moomoo
[144] Beta Bionics, Inc. SEC Filing - Stock Titan
Beta Bionics says Mint commercialization expected by end-Q2 2027, subject to FDA clearance - TradingView
Mint patch pump launch target set for Q2 2027 by Beta Bionics (NASDAQ: BBNX) - Stock Titan
No-recharge insulin patch pump targets 2027 launch pending FDA clearance - Stock Titan
BBNX Maintains by B of A Securities -- Price Target Lowered to $11.00 - GuruFocus
Beta Bionics Price Target Cut to $11.00/Share From $23.00 by B of A Securities - Moomoo
Beta Bionics, Inc. Stock 12‑Month Price Target Cut to $19.18, Implies 103% Upside - TradingView
BofA Adjusts Price Target on Beta Bionics to $11 From $23 - Moomoo
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Cuts Target Price to $11 - Moomoo
Beta Bionics (BBNX) Stock News, Page 3 - Stock Titan
BBNX Forecast — Price Target — Prediction for 2027 - TradingView
Beta Bionics | SCHEDULE 13G/A: Others - Moomoo
Eventide (BBNX) reports 5.95M shares — 13.4% stake in Beta Bionics - Stock Titan
RTW Investments reports 2.0M-share stake in Beta Bionics (NASDAQ: BBNX) - Stock Titan
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans - Yahoo Finance
BBNX: Mint patch pump launch set for end of 2027, with pharmacy channel driving growth - TradingView
Farallon and Zone Holdings disclose ownership in Beta Bionics (BBNX) — 13G/A - Stock Titan
Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation - Yahoo Finance
Number of shareholders of Beta Bionics, Inc. – NASDAQ:BBNX - TradingView
Soleus group files 9.8% stake in Beta Bionics (NASDAQ: BBNX) - Stock Titan
Beta Bionics, Inc. (BBNX) Stock Analysis: Exploring a Potential 93% Upside in Medical Devices - DirectorsTalk Interviews
A Quick Look at Today's Ratings for Beta Bionics(BBNX.US), With a Forecast Between $16 to $20 - Moomoo
Beta Bionics, Inc. (BBNX) soars 10.3%: Is further upside left in the stock? - MSN
Beta Bionics (BBNX) price target decreased by 11.15% to 20.99 - MSN
Midday Stock Roundup: Tech stocks rally - Orange County Business Journal
Beta Bionics, Inc. (BBNX) reports Q1 loss, misses revenue estimates - MSN
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):